BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 23142561)

  • 21. Correlation of Luminex-Based Single Antigen Based Results With Complement-Dependent Cytotoxicity Crossmatch and Flow Cytometry Crossmatch Results: A Single-Center Experience From Istanbul.
    Oguz SR; Sinangil A; Barlas S; Ciftci HS; Ulusoy E; İzgi DK; Ogret Y; Ecder T; Akin B
    Transplant Proc; 2023 Mar; 55(2):303-308. PubMed ID: 36890054
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of donor-specific HLA antibodies: A retrospective observation in 350 renal transplant cases.
    Pandey P; Pande A; Mandal S; Marik A; Devra AK; Sinha VK; Bhatt AP; Gajway SY; Singh RK; Mishra S; Jha S
    Transpl Immunol; 2023 Apr; 77():101783. PubMed ID: 36608831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C1q-binding DSA and allograft outcomes in pediatric kidney transplant recipients.
    Hayde N; Solomon S; Caglar E; Ge J; Qama E; Colovai A
    Pediatr Transplant; 2021 Mar; 25(2):e13885. PubMed ID: 33131194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.
    Chen G; Sequeira F; Tyan DB
    Hum Immunol; 2011 Oct; 72(10):849-58. PubMed ID: 21791230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death.
    Fidler SJ; Irish AB; Lim W; Ferrari P; Witt CS; Christiansen FT
    Transpl Immunol; 2013 Jun; 28(4):148-53. PubMed ID: 23665534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
    Tait BD; Süsal C; Gebel HM; Nickerson PW; Zachary AA; Claas FH; Reed EF; Bray RA; Campbell P; Chapman JR; Coates PT; Colvin RB; Cozzi E; Doxiadis II; Fuggle SV; Gill J; Glotz D; Lachmann N; Mohanakumar T; Suciu-Foca N; Sumitran-Holgersson S; Tanabe K; Taylor CJ; Tyan DB; Webster A; Zeevi A; Opelz G
    Transplantation; 2013 Jan; 95(1):19-47. PubMed ID: 23238534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complement-dependent cytotoxicity crossmatch in solid organ transplantation: The gold standard or golden history?
    Tafulo S; Osório E; Mendes C; Liwski R
    Hum Immunol; 2024 Jan; 85(1):110734. PubMed ID: 38030522
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C1q Donor-Specific Antibody Associates with Post-transplant Biopsy Findings in Highly- Sensitized Kidney Transplant Recipients.
    Kuppachi S; Holanda D; Gallegos S; Field EH
    Clin Transpl; 2016; 32():127-134. PubMed ID: 28564530
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accuracy of virtual crossmatch (VXM) prediction of physical crossmatch (PXM) results of donor specific antibody (DSA) in routine pretransplant settings-a single-center experience.
    Olszowska-Zaremba N; Zagożdżon R; Gozdowska J
    Transpl Immunol; 2022 Jun; 72():101583. PubMed ID: 35314352
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virtual crossmatch in kidney transplantation.
    Piazza A; Ozzella G; Poggi E; Caputo D; Manfreda A; Adorno D
    Transplant Proc; 2014 Sep; 46(7):2195-8. PubMed ID: 25242749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of Complement-Binding Capacity of HLA Antibodies Based on Mean Fluorescence Intensity.
    Zhao J; Fu YX; Yang T; Shen ZY; Wu CL
    Transplant Proc; 2016; 48(6):2235-40. PubMed ID: 27569975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
    Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
    Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
    Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
    Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of Luminex-based donor-specific antibody mean fluorescence intensity values with complement-dependent cytotoxicity & flow crossmatch results in live donor renal transplantation.
    Baranwal AK; Bhat DK; Goswami S; Agarwal SK; Kaur G; Kaur J; Mehra N
    Indian J Med Res; 2017 Feb; 145(2):222-228. PubMed ID: 28639599
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel Flow Cytometry-Based Method for Detection of Anti-HLA Complement Activating Donor-Specific Antibodies in Renal Transplant Recipients and Its Comparison With Other Conventional Detection Methods.
    Rani L; Singh H; Saikia B; Aggarwal R; Kumar Y; Kumar M; Chhabra S; Kumar M; Kumar B; Kumar V; Das P; Sharma A; Ramchandran R; Kohli HS; Minz RW
    Transplant Proc; 2023; 55(1):134-139. PubMed ID: 36609023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of complement (C1q, C3d) binding De Novo donor-specific HLA antibody in kidney transplant recipients.
    Lee H; Han E; Choi AR; Ban TH; Chung BH; Yang CW; Choi YJ; Oh EJ
    PLoS One; 2018; 13(11):e0207434. PubMed ID: 30427941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Positive virtual crossmatch with negative flow crossmatch results in two cases.
    Jacob EK; De Goey SR; Gandhi MJ
    Transpl Immunol; 2011 Jul; 25(1):77-81. PubMed ID: 21641997
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
    Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
    Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. C1q Test for Identification of Sensitized Liver Recipients at Risk of Early Acute Antibody-Mediated Rejection.
    Kozlowski T; Weimer ET; Andreoni K; Schmitz J
    Ann Transplant; 2017 Aug; 22():518-523. PubMed ID: 28839122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.